Bethesda II、III、IV类甲状腺结节中DICER1突变与BRAFV600E互斥
该研究纳入899例Bethesda II、III、IV类甲状腺细针穿刺(FNA)标本,检测DICER1外显子24/25、TERT启动子及BRAFV600E突变。DICER1突变见于52例(II类6.2%、III类4.9%、IV类10.4%),且与BRAFV600E互斥;III类中DICER1突变者均为AUS-other。
要点
- DICER1突变在Bethesda II、III、IV类结节中均可检出,IV类频率最高(10.4%)。
- Bethesda III类中BRAFV600E与DICER1突变互斥,提示DICER1突变结节不太可能为BRAF突变癌。
- DICER1突变者更年轻、结节体积更大,III类突变FNA均分类为AUS-other。
核心结论
- DICER1突变结节不太可能为BRAF突变癌,DICER1与BRAFV600E在Bethesda III类中互斥。
研究设计与样本
- 单中心连续收集1年内诊断为Bethesda II、III、IV类的FNA病例,共899例患者。
- 所有病例Sanger测序检测DICER1外显子24/25和TERT启动子突变,Bethesda III和IV类用ARMS-PCR检测BRAFV600E。
主要发现
- DICER1突变共52例:Bethesda II类20/322(6.2%)、III类25/510(4.9%)、IV类7/67(10.4%)。
- Bethesda III类510例中,76例携带BRAFV600E突变,25例携带DICER1突变,二者互斥。
- Bethesda II和III类中,DICER1突变者较无突变者更年轻且结节体积更大。
- 所有DICER1突变的Bethesda III类FNA均分类为AUS-other。
- 2例FNA样本检出TERT启动子突变(c.-118G>T和c.-144C>T)。
临床怎么用
- Bethesda III类结节若检出DICER1突变,可提示非BRAF突变癌,辅助细胞学诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to investigate the prevalence and cytological features of Dicer 1, Ribonuclease III (DICER)-mutant fine-needle aspiration (FNA) specimens in thyroid nodules classified as Bethesda II, III, and IV categories. The authors also sought to explore the relationship between DICER1 and BRAFV600E mutations in Bethesda III thyroid nodules. METHODS: The authors collected a series of consecutive FNA cases diagnosed as Bethesda category II, III, and IV from a medical center over the course of 1 year. DICER1 exons 24 and 25 and TERT promoter mutations were detected by Sanger sequencing in all cases, and BRAFV600E mutations were detected by amplification refractory mutation system PCR in Bethesda III and IV cases. RESULTS: A total of 899 patients were included in the study. DICER1 mutations were identified in 52 patients: 20 in Bethesda category II (6.2%, 20 of 322), 25 in Bethesda category III (4.9%, 25 of 510), and seven in Bethesda category IV (10.4%, 7 of 67). Among the 510 Bethesda III FNA samples, 76 harbored the BRAFV600E mutation and 25 harbored DICER1 mutations. BRAFV600E and DICER1 mutations were mutually exclusive. In Bethesda category II and III cases, patients with DICER1-mutant nodules were younger and had larger nodule volumes compared to those without DICER1 mutations. All DICER1-mutant Bethesda III FNAs were classified as atypia of undetermined significance (AUS)-other. TERT promoter mutations (c. -118G>T and c. -144 C>T) were identified in two FNA samples. CONCLUSION: The findings of this study suggest that DICER1-mutant nodules are unlikely to be BRAF-mutant carcinomas. Further study of the molecular characteristics of DICER1-mutant FNAs will contribute to more accurate cytological diagnosis.
引用
- Wang Y, Li G, Kong W, et al. DICER1 mutations in Bethesda category II, III, and IV thyroid nodules: A mutually exclusive relationship with BRAFV600E mutation. Cancer Cytopathol. 2025. PMID: 40608056. doi:10.1002/cncy.70029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。